Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lexaria Bioscience Corp.LEXX · Entity 7641 | Director | May 15, 2025 | May 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lexaria Bioscience Corp.
Report date May 15, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2030-05-15 | Direct | 43,000 |
Reported balance
After 2025-05-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-05-15 · Grant · Acquired 11,000 · Balance 43,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-02-01 | Direct | 3,400 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 3,400 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2027-03-08 | Direct | 6,800 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 6,800 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2027-10-12 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 10,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2028-07-25 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 15,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2029-04-26 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 20,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2029-07-26 | Direct | 32,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 32,000 |
| common sharesSEC Table I · non-derivative | Direct | 10,917 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,917 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 16, 2025 16:30 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 11,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001348362-25-000004 · primary_doc.xml · derivative · entry 8 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Shares · 11,000 shares Expires 2030-05-15 Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 11:39 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001348362-24-000004 · primary_doc.xml · derivative · entry 7 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Shares · 12,000 shares Expires 2029-07-26 Read SEC document |
| April 26, 2024 Filed May 10, 2024 16:52 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 5,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001855763-24-000006 · primary_doc.xml · derivative · entry 6 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 5,000 shares Expires 2029-04-26 Read SEC document |
| July 25, 2023 Filed Jul 25, 2023 13:56 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 5,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001855763-23-000003 · primary_doc.xml · derivative · entry 5 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 5,000 shares Expires 2028-07-25 Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 17:25 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 3,200 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001855763-22-000016 · primary_doc.xml · derivative · entry 4 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 3,200 shares Expires 2027-10-12 Read SEC document |
| May 24, 2022 Filed May 25, 2022 13:48 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | Grantcommon shares | 5,000 | $1.96 | $9,790.00 |
DisclosureSEC source: 0001855763-22-000006 · primary_doc.xml · nonDerivative · entry 2 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,917 Read SEC document |
| May 20, 2022 Filed May 24, 2022 13:06 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | Grantcommon shares | 1,799 | $2.01 | $3,610.59 |
DisclosureSEC source: 0001855763-22-000005 · primary_doc.xml · nonDerivative · entry 2 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,917 Read SEC document |
| May 19, 2022 Filed May 19, 2022 16:47 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | Grantcommon shares | 1,501 | $2.01 | $3,017.01 |
DisclosureSEC source: 0001855763-22-000004 · primary_doc.xml · nonDerivative · entry 3 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,118 Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:47 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | Grantcommon shares | 1,700 | $2.01 | $3,413.60 |
DisclosureSEC source: 0001855763-22-000004 · primary_doc.xml · nonDerivative · entry 2 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,617 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 17:32 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 3,400 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001855763-22-000003 · primary_doc.xml · derivative · entry 3 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Shares · 3,400 shares Expires 2027-03-08 Read SEC document |
| February 01, 2021 Filed Jul 21, 2021 13:32 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 3,400 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001855763-21-000021 · primary_doc.xml · derivative · entry 2 REESE ALBERT L JR · CIK 0001244736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,400 Underlying: Common Shares · 3,400 shares Expires 2026-02-01 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.